Gastric Cancer Third Line — Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
Citation(s)
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma